Open AccessEfficacy of Oral Febuxostat drug for Slowing the Glomerular Filtrate Rate Decline in Patients With Chronic Kidney Disease and Asymptomatic Hyperuricemia: A 6-Month, Single-Blind, Randomized, Placebo-Controlled Trial
Author(s) -
Abdul Malikc Mujahid,
M. Umar Farooq,
Rashid Karim,
Mehriq Fatima
Publication year - 2022
Publication title -
international journal of current research and review
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.112
H-Index - 4
eISSN - 2231-2196
pISSN - 0975-5241
DOI - 10.31782/ijcrr.2022.14805
Subject(s) - febuxostat , medicine , hyperuricemia , placebo , kidney disease , renal function , asymptomatic , randomized controlled trial , uric acid , pathology , alternative medicine
Hyperuricemia is considered as putative risk factor for progression of renal disease and febuxostat is used as an additional therapy for the control of lowering eGFRin CKD 3 and 4 patients. Objective: To determine the effect of febuxostat on eGFR among patients with chronic renal failure and increased uric acid levels. Materials and Methods: A single-Blind, RCT was conducted at Mayo Hospital, Lahore from 1st February, 2019 to 31st January, 2020. 330 Patients who full filled the inclusion criteria were enrolled. After the approval from Ethical Committee, written informed consent was taken and they were randomly divided into 2 groups. Group A patients received febuxostat 40 mg daily and group B received placebo with conventional therapy. Patients were evaluated for mean eGFR at the start, 3 and 6 months of treatment in both groups. Data was entered and analysed in SPSS ver: 21. Mean and standard deviation were calculated for numerical variables. Independent test was used to compare the means between the groups at baseline, 3 and 6 months with p < .05 as statistical significant. Results: In this study, efficacy was determined in terms of retardation in eGFR decline. At baseline and at 3rd month, no significant difference was found in eGFR in both groups however at 6th month mean eGFR was higher in Group A as compared to group B. Conclusion: The study concluded that febuxostat is more efficacious in slowing of declining e-GFR in patients with CKD stage 3 and 4.